a rare autosomal recessive disorder due to a defect in the lysosome trafficking regulator protein (LYST). [1] [2] [3] The resultant lysosomal dysfunction has a detrimental effect on many end organs. The most lethal and early manifestations are recurrent severe infections and hemophagocytic lymphohistiocytosis (HLH), a lymphoproliferative disorder referred to as an "accelerated phase." Variable degrees of oculocutaneous albinism and a bleeding tendency are also associated with the diagnosis. The presence of neutrophils with giant inclusion bodies is universally present and is pathognomonic for CHD. Neurologically, both central nervous system (CNS) and peripheral nervous system (PNS) problems are prevalent, although cognitive decline, parkinsonism, and cerebellar ataxia are the most debilitating.
In classic CHD (C-CHD), recurrent severe infections and transformation into an "accelerated phase," often result in early demise, usually within the first decade. Bone marrow transplantation (BMT) in patients with C-CHD has allowed survival into adulthood. A-CHD, observed in approximately 15% of patients, has a milder phenotype and is generally spared severe infections and the "accelerated phase". A-CHD may go undetected until an incidental blood smear containing abnormal neutrophils is observed, or during evaluation of unexplained neurodegeneration in the second or third decade. The severity of disease, C-CHD versus A-CHD, may be determined by the type of allelic mutation in LYST. 4 C-CHD gene defects are associated with either loss of function or proteinnull alleles, while A-CHD patients may be heterozygous with at least 1 missense mutant allele that encodes for proteins with partial function. 5 Both C-CHD and A-CHD are prone to develop a similar spectrum of neurologic disorders. CNS manifestations of CHD include progressive cognitive decline, basal ganglia dysfunction with resultant parkinsonism, and cerebellar ataxia. PNS manifestations include peripheral neuropathy and amyotrophy. PNS manifestations of C-CHD were initially recognized in the late 1960s with the description of an 11-year-old girl with CHD and a lymphoreticular malignancy who developed progressive weakness and areflexia. 6 Nerve biopsy showed massive cytoplasmic inclusions that were likely large lysosomes. Later autopsy studies on the same patient and 3 other children with C-CHD showed lysosomal and lipofuscin granules in dorsal spine ganglia, Schwann cells, astrocytes, nerve cells, and capillary endothelium. These peripheral nerves also showed widespread lymphohistiocytic infiltrations with axonal and myelin sheath degeneration, 7 although it is not clear if these were a manifestation of the "accelerated phase". Now that patients with C-CHD are frequently treated with BMT, which greatly diminishes the hematologic and infectious complications of the disease, they are surviving into adulthood. 8 Of interest, the peripheral and central neurological complications of CHD become more apparent as patients enter their second and third decades. 9 A-CHD patients are generally diagnosed later in life and survive into adulthood with a much reduced risk of "accelerated phase" or life threatening infections. As a result, A-CHD patients are not likely to undergo BMT. However, just like the C-CHD BMT patients, the A-CHD patients develop PNS and CNS neurological complications in later life. 10, 11 In A-CHD, sural nerve biopsy showed loss of myelinated and unmyelinated fibers with no evidence of demyelination on teased fiber and electron microscope examination that were concluded to be an axonal neuropathy. 11 Muscle biopsy in another A-CHD case showed neurogenic changes with fiber type grouping and atrophic fibers with acid phosphatase positive granules in the muscle fibers. 12 In this study, we present a summary of the electrodiagnostic findings of 18 patients with CHD, 9 with A-CHD and 9 with C-CHD. This represents the largest longitudinal study of PNS manifestations of CHD. Three detailed clinical cases highlight the spectrum of peripheral nerve manifestations observed in CHD. Prior clinical and molecular studies have been published for some of these patients. [13] [14] [15] MATERIALS AND METHODS Subjects. Patients were evaluated under clinical protocol 00-HG-0153 "Investigations into ChediakHigashi Syndrome and Related Disorders" (NCT 00005917) approved by the National Human Genome Research Institute Institutional Review Board. Written informed consent was obtained from all patients, including assent for children over the age of 7, when appropriate. The patients underwent multimodality assessment including clinical, genetic, functional, and electrodiagnostic evaluation. Many patients were evaluated serially, at yearly or longer intervals.
Clinical Neurophysiology Studies. Nerve conduction studies (NCS) were performed using standard methodology on a Nicolet Viking Select or EDX machine (Cardinal Health, Dublin, OH) and were compared with department-based normative values, included in Supplementary Table S1, available online. In general, the median and sural sensory nerves and the fibular and median motor nerves were tested, although the specific selection of nerves depended on clinical status. Needle electromyography (EMG) was performed using a concentric needle and filter settings of 2k-10K with spontaneous and motor unit potential (MUP) activity recorded according to standard methodology. When EMG was performed, it was generally limited to 2-3 muscles. Needle EMG was not well tolerated by several of the patients, thus information from this modality is limited. Active neurogenic changes in this study were marked by the presence of fibrillation potentials and positive sharp waves (fibs/psw) with or without the presence of complex repetitive discharges (CRDs). Chronic neurogenic changes in this study were marked by the presence of long duration and/or high amplitude MUPs with possible polyphasia. Generally, decreased recruitment was observed in the presence of neurogenic changes but was not specifically commented on in the tables.
RESULTS
Of the 18 patients evaluated with electrodiagnostic studies, 9 had A-CHD, and 9 had C-CHD (Table 1 ). Eight C-CHD patients had received BMTs. One C-CHD (C9) was atypical in his clinical presentation, because he survived into his 30s without life-threatening infections or the accelerated phase; however, his gene and protein studies were consistent with C-CHD, as he was homozygous for a nonsense mutation with no LYST protein produced. He never received a BMT but developed HLH at age 34 and succumbed to the disease. Based on the molecular and cell biologic findings and HLH presentation, he has been classified as C-CHD. Three representative patients, 2 with A-CHD and 1 with C-CHD, are described in further detail below.
Patient 1 (A4) was a 26-year-old Caucasian man who has A-CHD with parkinsonism and mild cognitive deficits. He was diagnosed with CHD at age 8 months. His clinical course was significant for frequent infections. At age 21, he began to develop progressive distal leg weakness and was noted to be areflexic. He subsequently has required bilateral ankle-foot orthoses for ambulation. In addition, his family reports decreased cognitive capacity. His initial electrodiagnostic studies, at age 26, showed low sural sensory nerve action potential (SNAP) amplitude (3 mV) and normal fibular compound muscle action potential (CMAP) amplitude (2.9 mV) ( Fig. 1) . Two years later, the sural SNAP could not be recorded, the median SNAP remained normal (19 mV), and the ulnar (11 mV) and radial (8 mV) SNAPs were low amplitude (details can be found in Supplementary Table S2) . Within 1 year, his right median CMAP abruptly decreased from 5.1 mV to 1.0 mV with clinical evidence of thenar atrophy. Three years later, the left median CMAP decreased from 9.6 mV to 2.3 mV. By comparison, the fibular CMAP recorded from the extensor digitorum brevis only gradually decreased from 2.9 mV to 1.3 mV over a 6-year period, and the ulnar CMAP remained stable. The motor and sensory conduction velocities were all normal, even in the low amplitude responses. For the motor NCS (MNCS), the fibular distal latencies became prolonged (5.3 ms to 7.4 ms) as the amplitude decreased, but other distal latencies and Fwave latencies were normal. Needle EMG studies, limited to leg muscles on the initial exam, showed active denervation with the presence 2 1 fib/psw in the tibialis anterior and 4 1 fib/psw in the medial gastrocnemius but not in the vastus lateralis. There were also mild chronic neurogenic changes with long duration MUPs and polyphasia in tibialis anterior and medial gastrocnemius. MUPs were not evaluated in the vastus lateralis, and he did not tolerate further EMG testing. His younger brother (A5) showed similar findings although less severe.
Patient 2 (A8) was a 38-year-old man of South Asian descent with A-CHD who presented in his late 20s with parkinsonian features of rigidity and masked facies. He had mild cognitive deficits but was still working. On exam, he was noted to have spastic paraparesis and parkinsonism. He had a thin body habitus, but no isolated muscle atrophy or fasciculations were noted. On electrodiagnostic studies, he had normal CMAP (fibular 7.7 mV, median 12.9 mV) and SNAP (sural 13 mV, median 55 mV, ulnar 31 mV, radial 33 mV) amplitudes. The conduction velocities, distal latencies, and F-wave latencies were also normal. The needle EMG study showed mild active denervation in medial gastrocnemius and tibialis anterior with 1-2 1 fibs/psw. Chronic neurogenic changes were noted on exam with the presence of high amplitude, long duration MUPs in the tibialis anterior, vastus lateralis, but less evident in the medial gastrocnemius, first dorsal interosseous, and triceps. The biceps did not have large MUPs but was mildly fibrotic on insertion. Fasciculation potentials were also observed in the tibialis anterior and first dorsal interosseus. Studies performed 1 year later did not show any change.
He has a 43-year-old sister with A-CHD (A7) who has parkinsonism and reported cognitive decline since age 30. She also presented with a spastic paraparesis and became wheel-chair restricted, although strength in her arms was generally preserved. Her electrodiagnostic studies showed low amplitude or nonrecordable CMAPs (fibular, no response [NR]; tibial 0.4 mV) and SNAPs (sural, NR) in the legs but normal potentials (median motor 7.1 mV, median sensory, 46 mV, ulnar 22 mV, radial 22 mV) in the arm. The needle EMG showed active denervation with the presence of 2-4 1 fibs/psw in the tibialis anterior, vastus lateralis, triceps brachii, and a year later also the biceps brachii. CRDs were observed the second year in the tibialis anterior and vastus lateralis. Chronic neurogenic changes with large MUPs and some polyphasia were observed in all muscles sampled. On the third year of evaluation, only the trapezius was sampled and showed large MUPs without fibs/psw. A third sibling, a 33-year-old man (A10), with A-CHD also had difficulties with ambulation. However, he had a severe lumbar arteriovenous (AV) fistula that likely caused a polyradiculopathy. The siblings were not the product of a consanguineous relationship, although both parents were from the same region in Pakistan. The 2 patients, A8 and A7, have consanguineous relationships with their first cousins. Their Patient 3 (C3) is a 30-year-old woman with C-CHD, who had BMT at age 10. She had a history of learning difficulties, although she completed high school and received an AA degree. At age 8, she developed the "accelerated phase" and was treated successfully. At age 10, before BMT, she had an episode of quadriparesis with complete recovery. At age 25, she developed progressive bilateral foot drop. On neurological exam, she had bilateral leg weakness with greater weakness in distal leg muscles and normal upper extremity (UE) exam. She had diminished pinprick and vibration sensation in both distal legs. She was areflexic except for 1 1 at the biceps. Her gait was widebased and slow. On NCS, she had nonrecordable sural and low median (9 mV), ulnar (8 mV), and radial (5 mV) SNAPs (Fig. 2) . The conduction velocities were slow (39 m/s) for only the median and ulnar sensory nerves. Her fibular and tibial CMAPs were nonrecordable, but they were normal in the median (7.3 mV) and ulnar (6.9 mV) motor nerves.
After 4 years, her median CMAP (2.4 mV) also became abnormal. Her median distal latency became prolonged (4.3 to 5.9 ms), and the conduction velocity also gradually slowed (50 to 38 m/ s). This may have represented median nerve entrapment at the wrist, as there was no other electrophysiological evidence of a demyelinating disorder. The sensory SNAP amplitudes and conduction velocities did not change much during the followup periods. Initial needle EMG showed active neurogenic changes with 1-2 1 fib/psw and CRDs in the medial gastrocnemius. Chronic neurogenic changes with large MUPs were noted in the vastus lateralis, medial gastrocnemius, and biceps brachii. Some connective tissue replacement was noted in the vastus lateralis. Four years later, needle EMG of only the biceps brachii and deltoid muscles showed active denervation with 1-2 1 fibs/psw and chronic neurogenic changes with large MUPs.
A summary of the 3 patients shows either a pattern of progressive distal weakness with axonal sensorimotor neuropathy (Patient 1, A4), diffuse muscle weakness with a motor neuropathy or neuronopathy (Patient 2, A8, A7), or a possible combination of both length-dependent sensorimotor neuronopathy and more diffuse motor neuropathy /neuronopathy. Summary of the clinical and electrodiagnostic findings of all the A-CHD and C-CHD patients are presented in Tables 2 and 3 with specific details of the serial EDx findings (motor and sensory amplitudes and EMG findings) presented in Supplementary Tables S2 and S3. For the A-CHD cohort, there were 7 men and 2 women with a mean age of 27.4 years (range, 17-43 years) at the time of initial study. All patients received follow-up evaluations for 2-7 years ( Table  2 ). The most common clinical finding was areflexia; 6 patients were completely areflexic, and 3 had absent ankle reflexes only. Five patients had progressive leg weakness, and 3 patients had leg weakness followed by arm weakness. Coexisting neurological entities included parkinsonism (4 patients), cerebellar ataxia (2 patients), and most had cognitive impairment. On initial evaluation with NCS, 3 patients (A1, A3, A4) had electrodiagnostic evidence of an axonal sensory polyneuropathy with low or absent sural SNAPs.
During the follow-up period, 3 patients (A2, A5, A6) had decrease or loss of their sural SNAPs, and 2 patients (A2, A4) had decrease in fibular CMAPs. Needle EMG was performed on the 9 A-CHD patients and showed neurogenic abnormalities in 6 (A4-A9). The 3 patients with normal EMG had very limited sampling of muscles and were only examined once or twice early in followup. At the end of the follow-up period, only 1 patient (A1) had an isolated sensory neuropathy without additional abnormal electrodiagnostic findings, and she did not develop distal weakness. Four patients (A6, 8, 9 ), including the patient with an A-V fistula (A10), had normal NCS but evidence of chronic neurogenic changes by needle EMG. Three patients, with either abnormal motor and sensory NCS (SNCS) (A4, A7) or only low amplitude SNAPs (A5), had neurogenic changes on needle EMG. Two patients, 1 with low CMAP and SNAP amplitudes (A2) and the other with only low amplitude SNAPs (A3), had normal EMG findings, but the study was limited to 1 distal leg muscle sampled in an early visit. Both of these patients, a sibling pair, worsened clinically over the subsequent 7 years, particularly the older brother. For the NCS, the conduction velocities, distal latencies, and F-wave latencies, in general, were normal and did not suggest a demyelinating process. Overall, the findings in these 9 patients showed varying degrees of a combination of length-dependent polyneuropathy and a possible motor neuronopathy.
Of the 9 C-CHD patients, there were 4 adults (mean, 26.0 years; range, 21-31 years) and 5 children (mean, 4.8 years; range, 4-5 years). Three adults (C2, C3, C6) were initially evaluated 18-22 years post-BMT. The 4 th adult (C9) was not treated with BMT. Patient C3 had serial studies over 4 years, and patient C2 was seen twice during a 5-year period. The 3 older patients (C3, C6, C9) had hypo-or areflexia and bilateral leg weakness. The 21-year-old patient (C2) only had areflexia on the initial exam, but at age 25 developed mild distal weakness and ataxia. On initial electrodiagnostic exam, the 2 oldest patients (C3, C9) had absent sural SNAPs with low UE SNAPs. The lower extremity (LE) CMAPs were either not recordable (C3) or low amplitude (C9) but normal in the UE. Follow-up studies for patient C3 were performed 5 years later and showed that the median CMAP had decreased by 70%, but the ulnar CMAP remained stable. Patient C6 had absent sural SNAPs with low UE SNAPs but CMAPs. There were minor abnormalities in the conduction velocity, distal latency, and F-wave latencies which did not suggest a demyelinating disorder. All 3 patients had evidence of active and chronic neurogenic changes on needle EMG. The 21-year-old (C2) patient only had NCS performed; they were normal initially, but the sural SNAP became abnormal 5 years later. On clinical exam, the children had normal peripheral neurological exam, although they had mild cognitive deficits or speech delays. The 5 children had normal NCS, and 3 had normal needle EMG studies.
DISCUSSION
This study presents the long-term PNS sequelae in a large cohort of patients with CHD from both classic and atypical forms. In many cases, CNS manifestations of CHD appear to precede clinical signs of peripheral neuropathy; however, both A-CHD and C-CHD patients develop PNS manifestations by their second or third decades. The longitudinal NCS demonstrate a very gradual decrease in SNAP amplitude while MNCS may be punctuated with relatively acute loss of amplitudes, such as in the case of the median motor nerve in the first patient described above (patient A4). The most common PNS finding is a length-dependent sensory or sensorimotor polyneuropathy. This generally occurs in the clinical setting of areflexia and progressive distal leg weakness. Both A-CHD and C-CHD patients may also develop diffuse chronic neurogenic abnormalities that likely reflect a motor neuronopathy. The diffuse neurogenic findings were more frequently observed in the older individuals who clinically showed signs of both UE and LE weakness. The 5 children with C-CHD did not show signs of neuropathy or neuronopathy in keeping with the observation that it takes several decades for the PNS findings to become clinically apparent. Also, the fact that only the adults who had BMT developed neuropathy and not the children with BMT, suggests that the neuropathy is related to a degenerative process and is not related to conditioning regimens with chemotherapeutic agents given before BMT in childhood. It would be interesting to know whether an association exists between a specific type of CNS disorder and a particular pattern of PNS abnormalities. Of the 4 A-CHD patients with parkinsonism, 3 appeared to have diffuse chronic neurogenic findings, and only 1 had mild neurogenic findings in a distal muscle. Two A-CHD patients with cerebellar ataxia had sensorimotor neuropathies, but the data from the needle EMG was too limited to determine the extent of neurogenic abnormalities. The A-CHD patient with only a sensory neuropathy developed mild cerebellar symptoms after 6 years of follow-up and did not appear to have evidence of a motor neuronopathy. In the C-CHD patients, the 3 with chronic neurogenic abnormalities did not have evidence of parkinsonism, although 2 had evidence of incoordination. Overall, these observations are not sufficient to determine an association between specific CNS and PNS manifestations of CHD.
The particular genotype-phenotype correlation within the LYST gene may also play a role in determining certain predilections for specific types of neurologic impairment. A genotype-phenotype correlation exists in the 2 mouse models of CHD. The beige mouse closely mirrors C-CHD with pigment dilution, enlarged granules within multiple cell types, including leucocytes, and granulocyte dysfunction, 16, 17 but it lacks neurologic manifestations. The second mouse model, Lyst Ing3618 /LystIng3618 , created through ENU mutagenesis, is homozygous for a missense mutation. 18 This model has a predominant neurologic phenotype with blunted pigment dilution, but lack of immunologic defects. This model more closely recapitulates the A-CHD phenotype. Unfortunately, in human CHD, a specific correlation between mutation types and 19 which may result in gradual accumulation of toxic substances within the cell. This results in oxidative injury to the cell and neuronal cell death. Additionally, the aberrant accumulation of lysosomes interferes with the extensive membrane trafficking essential to neuronal viability and axonal transport mechanisms. 20, 21 Early reports of biopsies that showed profuse lymphohistiocytic infiltrates led to the impression that there was an inflammatory response. 7 These cases are likely limited to patients in the midst of the "accelerated phase" rather than the adult patients with either posttransplant C-CHD or A-CHD.
In C-CHD, BMT allows for correction of hematologic abnormalities related to lysosomal transport. It does not inhibit ongoing injury of neuroglial cells within the PNS and CNS. Likewise, A-CHD is not spared the long-term sequelae of neurologic injury. Except for 1 case report in which prednisolone was used to treat peripheral neuropathy, 22 there are no effective treatments for the neurological complications of CHD. Overall, the PNS manifestations of CHD are less debilitating than those in the CNS but may provide a convenient method of monitoring future treatments. CHD is a rare disorder that is important to consider in patients who present with PNS involvement such as distal motor and sensory impairment or foot drop. This is especially true if systemic disease features such as oculocutaneous albinism, pigment dilution, excess bleeding immune deficiency, and /or neurological problems, including early onset parkinsonism or cerebellar ataxia, are present. Diagnostic work-up would include examination of the peripheral blood smear for neutrophils with giant inclusions and genetic testing of the LYST gene. For C-CHD, BMT is a serious consideration to prevent the HLH, or the "accelerated phase", although one should understand that BMT does not appear to prevent future CHD-related neurological deficits. Currently, there is no effective targeted treatment to mitigate the ongoing nervous system involvement of CHD. There is a symptomatic response to L-Dopa for those patients with parkinsonism. Comprehensive rehabilitation and orthotics may provide substantial benefit for those with significant peripheral nervous system impairment.
